Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2007 on NSE
Last close ₹847.30up ₹10.85 (1.30%)BSE ₹846.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹836.45.
2 Nov: open ₹839.20, high ₹861.15, low ₹821.00
52-week range of traded prices to 2 Nov 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,074 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,09,48449.1% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 12 of 18.
Nov 2014
Sep 2014
30 Sep · Extension of Financial Year
Aug 2014
5 Aug · Board meeting
To take on record the unaudited financial results of the Company for the period from April 01, 2014 to June 30, 2014.
Jul 2014
14 Jul · Board meeting
Jun 2014
4 Jun · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Orchid Chemicals & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated,"We confirm that there are no material developments and plans other than those already communicated to the exchanges in line with the listing agreement. The company is unaware of the reason behind this price and volume increase."
May 2014
12 May · Results
Mar 2014
Feb 2014
11 Feb · Results
Jan 2014
Dec 2013
Nov 2013
Aug 2013
14 Aug · Management
Prof. Bala V Balachandran has resigned from the Board of the Company and Shri Sundaram Yuvaraj has been inducted into the Board of Orchid Chemicals and Phamaceuticals Limited with effect from August 14, 2013.6 Aug · Board meeting
To take on record the unaudited financial results of the Company for the period from April 01, 2013 to June 30, 2013, Q5 of the extended financial year 2012-2013.
Jul 2013
11 Jul · Extension of Financial Year
Jun 2013
26 Jun · Extension of Financial Year
24 Jun · Corporate Debt Restructuring
May 2013
Apr 2013
18 Apr · Board meeting
17 Apr · Updates
Orchid's Cephalosporin API manufacturing complex located in Alathur, Chennai has successfully cleared the USFDA inspection that it went through. The facility manufactures a range of oral and sterile Cephalosporin APIs and caters to the developed markets like USA, Europe and Japan.
Feb 2013
Jan 2013
Dec 2012